Genes Linked With Addiction to Psychostimulant Drugs Identified
Researchers discover correlation between methamphetamine-induced behavior and the expression of specific genes.
Complete the form below to unlock access to ALL audio articles.
Mice lacking the Period 2 (Per2) gene, a gene associated with circadian rhythm, are considered a potential animal model for studying vulnerability to drug abuse. However, their response towards methamphetamine and cocaine is not well understood. Now, researchers from Sahmyook University have demonstrated that mice lacking the Per2 gene shows stronger addictive response towards methamphetamine, with the activation of specific genes. These results suggest a unique effect of Per2 expression in determining vulnerability towards psychostimulants.
Psychostimulant drugs like methamphetamine (METH) and cocaine (COC) affect the brain and nervous system by boosting alertness, attention, and energy levels of the individual. However, their persistent use results in drug addiction, compromising the life of the individual and burdening the healthcare, social, and legal systems as a consequence. In order to develop effective prevention and treatment strategies for drug addiction, it is critical to explore how these drugs interact with the nervous system and understand the mechanism underlying the addictive responses of individuals towards psychostimulants.
In order to bridge this gap, a group of researchers from Korea and Germany, led by Assistant Professor Hee Jin Kim from Sahmyook University compared how Per2 KO mice and wild-type (WT) mice, i.e., mice with Per2, responded to repeated self-administered doses of METH and COC. Their findings, made available online on 2 May 2023, were published in Volume 126 of the Journal Progress in Neuropsychopharmacology & Biological Psychiatry on 30 August 2023.
The researchers first investigated the motivational effect of these drugs and their impact on the locomotor activity of the mice using specialized tests. They noted that Per2 KO mice showed a stronger addictive response to METH when compared to the WT mice. However, when it came to drugs like COC, both groups of mice responded in a similar manner. Highlighting the importance of this observation, Dr. Kim exclaims, “The higher sensitivity of Per2 KO mice to METH rather than COC helped us deduce that different genetic factors were at play behind vulnerability to different drugs.”
Probing further, the researchers used a technique that identifies the coding sequence of an RNA–RNA sequencing–to pin down the genes involved in these addictive responses. They identified 19 genes that were only activated in response to repeated doses of METH but not COC. Using existing data, the researchers could correlate these genes with those that are activated in the region of the brain that responds to drug addiction.
Finally, to identify if any of the genes expressed due to METH exposure corresponded with METH-induced behavior, the researchers correlated the mRNA expression levels with the locomotor activity tests in Per2 KO and WT mice. They found that two specific genes, Arc and Junb, were expressed only in Per2 KO mice on METH exposure.
Highlighting their study’s findings, Dr. Kim says, “Our findings indicate that Arc and Junb, along with Per2, could be used as markers for susceptibility to METH abuse. If we are able to confirm the role of Arc and Junb expression in vulnerability to drug abuse, they could even be considered as potential targets for treating or preventing drug abuse.”
In summary, by unraveling the genetic factors that influence how our brains respond to psychostimulant drugs like METH and COC, researchers can pave the way for more targeted and personalized approaches to tackling drug abuse. In this regard, this study could open doors to the development of more effective diagnostic, preventive and treatment strategies, and potentially save countless lives.
Reference: Sayson LV, Lee HJ, Ortiz DM, et al. The differential vulnerabilities of Per2 knockout mice to the addictive properties of methamphetamine and cocaine. Prog Neuro-Psychopharmacol Biol Psychiatry. 2023;126:110782. doi: 10.1016/j.pnpbp.2023.110782
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.